Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miltefosine vs Glucantime for Cutaneous Leishmaniasis
NCT00351520Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- May 2006
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of miltefosine in cutaneous leishmaniasis (CL) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Complete re-epithelization of all lesions. Started May 2006; status: completed.
02
Drugs
miltefosine
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT00351520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00351520.